Fiche publication
Date publication
janvier 2020
Journal
Frontiers in oncology
Auteurs
Membres identifiés du Cancéropôle Est :
Dr BRASSART-PASCO Sylvie
,
Dr MONBOISSE Jean-Claude
,
Pr RAMONT Laurent
,
Dr BRASSART Bertrand
,
Dr OUDART Jean-Baptiste
Tous les auteurs :
Nannan L, Oudart JB, Monboisse JC, Ramont L, Brassart-Pasco S, Brassart B
Lien Pubmed
Résumé
Extracellular vesicles (EVs) like exosomes and shed microvesicles are generated by many different cells. However, among all the cells, cancer cells are now recognized to secrete more EVs than healthy cells. Tumor-derived EVs can be isolated from biofluids such as blood, urine, ascitic fluid, and saliva. Their numerous components (nucleic acids, proteins, and lipids) possess many pleiotropic functions involved in cancer progression. The tumor-derived EVs generated under the influence of tumor microenvironment play distant roles and promote cellular communication by directly interacting with different cells. Moreover, they modulate extracellular matrix remodeling and tumor progression. Tumor-derived EVs are involved in pre-metastatic niche formation, dependent on the EV-associated protein receptors, and in cancer chemoresistance as they transfer drug-resistance-related genes to recipient cells. Recent advances in preclinical and clinical fields suggest their potential use as biomarkers for diagnosis and prognosis as well as for drug delivery in cancer. In this Review, we discuss EV characteristics and pro-tumor capacities, and highlight the future crucial impact of tumor-derived EVs in pancreatic cancer diagnosis and prognosis.
Mots clés
bioactivities, biomarkers, extracellular vesicle (EV), imaging in vivo, pancreatic cancer
Référence
Front Oncol. 2020 ;10:1456
